TRAIL R1/DR4/TNFRSF10A Protein, Human, Recombinant (hFc)

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis selectively via its interaction with the death receptors TRAILR1/DR4 and TRAILR2/DR5 in a wide range of cancers, while sparing normal cells. Despite its tremendous potential for cancer therapeutics, the translation of TRAIL into the clinic has been confounded by TRAIL-resistant cancer populations.

Pack Size	Availability	Price/USD
100 μg	5 days	$ 336.00
500 μg	5 days	$ 1,350.00
1 mg	5 days	$ 2,250.00

Pack Size

Availability

Price/USD

Quantity

100 μg

5 days

$ 336.00

500 μg

5 days

$ 1,350.00

1 mg

5 days

$ 2,250.00

Description

Species	Human
Expression System	HEK293
Tag	C-hFc
Accession Number	O00220
Synonyms	TRAIL R1, APO2, DR4, CD261, TRAIL-R, TNFRSF10A, MGC9365
Construction	Recombinant Human TRAIL R1/DR4/TNFRSF10A Protein is expressed from HEK293 with hFc tag at the C-Terminus. It contains Pro34-Asn239.[Accession \|O00220]
Protein Purity	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Molecular Weight	The protein has a predicted MW of 48.8 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Tris-Bis PAGE result.

Endotoxin	Less than 1EU per μg by the LAL method.
Formulation	Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Stability & Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Research Background	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis selectively via its interaction with the death receptors TRAILR1/DR4 and TRAILR2/DR5 in a wide range of cancers, while sparing normal cells. Despite its tremendous potential for cancer therapeutics, the translation of TRAIL into the clinic has been confounded by TRAIL-resistant cancer populations.